MiNK Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; comparisons are with FY2021. MiNK is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies. It had no approved products and generated no product revenue.
Financial performance and position
| Metric | FY2022 / Dec. 31, 2022 | FY2021 / Dec. 31, 2021 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $23.1 million | $14.0 million |
| General and administrative expense | $7.8 million | $4.6 million |
| Operating loss | $30.9 million | $28.4 million |
| Net loss | $28.0 million | $30.2 million |
| Net loss per share | $0.83 | $1.16 |
| Cash and cash equivalents | $19.6 million | $38.9 million |
| Net cash used in operating activities | $18.9 million | $12.8 million |
| Total assets | $21.5 million | $40.2 million |
| Total liabilities | $21.9 million | $16.5 million |
| Stockholders’ equity (deficit) | $(0.4) million | $23.8 million |
Margins: Not meaningful; the company reported no product revenue. FY2022 R&D expense rose about 66% and G&A about 69%, driven by clinical and preclinical work, personnel and manufacturing internalization, stock-based compensation, and professional fees. Operating loss widened, while net loss narrowed because FY2021 included a $9.8 million noncash fair-value charge and $2.4 million of interest expense on the Agenus convertible note; the note converted to shares in 2021. FY2022 other income included a $2.7 million gain related to partial forgiveness/reduction of the Walloon Region advance liability.
Cash declined by $19.3 million during FY2022. MiNK reported $9.1 million due to related parties at year-end, alongside $12.7 million of current liabilities; the filing says Agenus agreed in 2023 not to require repayment of the related-party balance before March 31, 2024. The company reported no product sales or royalty revenue. Its prior convertible affiliated note was converted into common stock in October 2021; no balance remained at FY2022 year-end.
Business, pipeline and changes
- agenT-797: The lead, native allogeneic iNKT candidate was in three Phase 1 programs: solid tumors, multiple myeloma and viral ARDS. Management reported early solid-tumor activity, including lesion reductions or disease stabilization; tolerability up to 1 billion cells per dose and biomarker suppression in multiple myeloma; and 70% survival in the ARDS study versus cited comparison data of approximately 10%–22%. These are early, company-reported findings, not confirmatory evidence.
- Engineered candidates: MiNK-413 (BCMA-CAR-iNKT) and MiNK-215 (FAP-CAR-iNKT) remained preclinical. The filing describes encouraging preclinical results and IND-enabling work underway in 2023. Management’s stated plan included MiNK-215 IND filing expectations for 2024.
- Operations and funding: MiNK continued to rely on Agenus for facilities and certain administrative, research, legal and regulatory services. It described scaling internal, automated cGMP manufacturing. Agenus held approximately 78% of MiNK’s common stock, giving it substantial voting influence.
Outlook, risks and unusual items
- Management expected year-end 2022 cash to fund operations and capital needs for more than one year from the date the financial statements were issued, while noting that plans could change and spending would be adjusted to preserve liquidity. There is no specific revenue or earnings guidance; the company expects operating losses and negative cash flows for the foreseeable future.
- Potential funding sources include collaborations, licensing or partnering, debt, equity issuance, and—if needed—borrowing from Agenus. Additional financing is not committed and could dilute shareholders or require rights to be ceded.
- The Walloon Region obtained a default judgment seeking repayment of approximately $2.2 million. MiNK reduced the liability and recorded a $2.7 million gain; it said it was evaluating the claim and its options. The matter remains a contingency.
- The filing disclosed the March 2023 closure of Silicon Valley Bank. MiNK said it regularly held cash at financial institutions above FDIC limits and warned that future financial-sector disruption could impair access to cash; the filing does not state that MiNK incurred a loss on its SVB deposits.
- Key risks include early-stage and unverified clinical results, trial enrollment and regulatory uncertainty, manufacturing scale and quality, competition, dependence on additional capital, intellectual-property protection, and reliance on Agenus and third parties. The company also noted slower ARDS enrollment as COVID-19 hospitalizations declined.
- KPMG issued an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022; auditor attestation was not required for the company.
Important facts for investors to verify
- Updated and final clinical data for agenT-797, including trial size, follow-up, control selection, safety, durability and statistical limitations—especially the ARDS survival comparison.
- Cash use, financing runway, future capital needs and the timing and terms of any financing or partnering transactions.
- The balance, terms and repayment timing of amounts due to Agenus, and the cost and continuity of shared services and facility access.
- The status and potential financial consequences of the Walloon Region judgment and remaining liability.
- Progress toward IND filings, manufacturing scale-up and reproducible product release for MiNK-413, MiNK-215 and agenT-797.